[{"address1": "170 Park Avenue", "city": "Florham Park", "state": "NJ", "zip": "07932", "country": "United States", "phone": "908 768 2170", "website": "https://www.celularity.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.", "fullTimeEmployees": 120, "companyOfficers": [{"maxAge": 1, "name": "Dr. Robert Joseph Hariri M.D., Ph.D.", "age": 64, "title": "Founder, CEO & Chairman", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 1234342, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John R. Haines", "age": 66, "title": "Senior EVP, Global Manager & Chief Administrative Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 534615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Adrian  Kilcoyne M.B.A., M.D., M.P.H.", "age": 52, "title": "Executive VP, Chief Medical Officer and Head of Global Affairs, Patient Safety & Patient Affairs", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 590540, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David C. Beers C.F.A.", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 455021, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ramji  Krishnan", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Carlos  Ramirez", "title": "SVP of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kyle Harold Fletcher Esq.", "age": 38, "title": "Executive VP, General Counsel & Chief Compliance Officer", "yearBorn": 1985, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen A. Brigido D.P.M.", "age": 47, "title": "President of Degenerative Diseases", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Sharmila  Koppisetti M.D.", "title": "Senior Vice President of Clinical Dev. Immunology & Drug Safety", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tim  Wilk", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.72, "open": 2.7008, "dayLow": 2.67, "dayHigh": 2.93, "regularMarketPreviousClose": 2.72, "regularMarketOpen": 2.7008, "regularMarketDayLow": 2.67, "regularMarketDayHigh": 2.93, "beta": 0.443, "forwardPE": -4.982456, "volume": 3105, "regularMarketVolume": 3105, "averageVolume": 16370, "averageVolume10days": 15220, "averageDailyVolume10Day": 15220, "marketCap": 62436264, "fiftyTwoWeekLow": 1.59, "fiftyTwoWeekHigh": 7.97, "priceToSalesTrailing12Months": 2.7419202, "fiftyDayAverage": 2.98784, "twoHundredDayAverage": 3.33846, "currency": "USD", "enterpriseValue": 124988152, "floatShares": 10959330, "sharesOutstanding": 21984600, "sharesShort": 713980, "sharesShortPriorMonth": 727055, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0325, "heldPercentInsiders": 0.53415, "heldPercentInstitutions": 0.14764, "shortRatio": 66.58, "shortPercentOfFloat": 0.109, "bookValue": 2.114, "priceToBook": 1.3434247, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.609, "netIncomeToCommon": -196295008, "trailingEps": -110.2, "forwardEps": -0.57, "enterpriseToRevenue": 5.489, "enterpriseToEbitda": -1.861, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CELU", "underlyingSymbol": "CELU", "shortName": "Celularity Inc.", "longName": "Celularity Inc.", "firstTradeDateEpochUtc": 1565271000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "acab037e-115e-3a22-b200-e5ce523f37ff", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.84, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 227000, "totalCashPerShare": 0.01, "ebitda": -67155000, "totalDebt": 65417000, "quickRatio": 0.153, "currentRatio": 0.294, "totalRevenue": 22771000, "debtToEquity": 159.709, "revenuePerShare": 1.278, "returnOnAssets": -0.17543, "returnOnEquity": -1.63674, "freeCashflow": -23696750, "operatingCashflow": -38685000, "earningsGrowth": -0.613, "revenueGrowth": 1.933, "grossMargins": 0.29665002, "ebitdaMargins": -2.94915, "operatingMargins": -0.89548, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]